Downregulation of tumor protein 53-inducible nuclear protein 1 expression in hepatocellular carcinoma correlates with poor prognosis

Deng,Yan; Li,Ai‑Min; Zhao,Xin‑Mei; Song,Zhang‑Juan; Liu,Si‑De

doi:10.3892/ol.2016.5537

Downregulation of tumor protein 53-inducible nuclear protein 1 expression in hepatocellular carcinoma correlates with poor prognosis

Authors:
- Yan Deng
- Ai‑Min Li
- Xin‑Mei Zhao
- Zhang‑Juan Song
- Si‑De Liu
View Affiliations

Affiliations: Department of Gastroenterology, Southern Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: December 27, 2016 https://doi.org/10.3892/ol.2016.5537
Pages: 1228-1234
Copyright: © Deng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression of tumor protein 53-inducible nuclear protein 1 (TP53INP1) is upregulated in certain cancers and downregulated in others. However, its expression in hepatocellular carcinoma (HCC) is not clear. The present study aimed to investigate the expression and prognostic value of TP53INP1 and its association with clinicopathological parameters in HCC. TP53INP1 expression in HCC tissue samples was examined via immunohistochemistry, western blotting and reverse transcription‑quantitative polymerase chain reaction. Expression was categorized as high or low. The correlations of TP53INP1 expression with clinical characteristics and patients' prognoses were determined. TP53INP1 was frequently decreased in HCC tissues compared with adjacent non‑tumorous liver tissues. This decreased expression was significantly associated with American Joint Committee on Cancer stage (P=0.014) and vascular invasion (P=0.024). Kaplan‑Meier analysis further revealed that recurrence‑free survival (RFS) (P=0.001) and overall survival (OS) (P=0.002) were significantly worse among patients with low TP53INP1 expression than among those with high TP53INP1 expression. In addition, multivariate analyses revealed that TP53INP1 was an independent predictor of OS [hazard ratio (HR)=2.680, 95% confidence interval (CI)=1.087‑6.608, P=0.032) and RFS (HR=2.284, 95% CI=1.157‑4.511, P=0.017). In conclusion, the expression of TP53INP1 was decreased in HCC, and TP53INP1 downregulation was an independent predictor of poor prognosis in patients with HCC.

View Figures

View References

1	Ringer L, Sirajuddin P, Tricoli L, Waye S, Choudhry MU, Parasido E, Sivakumar A, Heckler M, Naeem A, Abdelgawad I, et al: The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells. Oncotarget. 5:10678–10691. 2014. View Article : Google Scholar : PubMed/NCBI
2	Okamura S, Arakawa H, Tanaka T, Nakanishi H, Ng CC, Taya Y, Monden M and Nakamura Y: p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Mol Cell. 8:85–94. 2001. View Article : Google Scholar : PubMed/NCBI
3	Tomasini R, Samir AA, Pebusque MJ, Calvo EL, Totaro S, Dagorn JC, Dusetti NJ and Iovanna JL: P53-dependent expression of the stress-induced protein (SIP). Eur J Cell Biol. 81:294–301. 2002. View Article : Google Scholar : PubMed/NCBI
4	Tomasini R, Samir AA, Vaccaro MI, Pebusque MJ, Dagorn JC, Iovanna JL and Dusetti NJ: Molecular and functional characterization of the stress-induced protein (SIP) gene and its two transcripts generated by alternative splicing. SIP induced by stress and promotes cell death. J Biol Chem. 276:44185–44192. 2001. View Article : Google Scholar : PubMed/NCBI
5	Nowak J, Depetris D, Iovanna JL, Mattei MG and Pebusque MJ: Assignment of the tumor protein p53 induced nuclear protein 2 (TP53INP2) gene to human chromosome band 20q11.2 by in situ hybridization. Cytogenet Genome Res. 108:3622005.PubMed/NCBI
6	Tomasini R, Samir AA, Carrier A, Isnardon D, Cecchinelli B, Soddu S, Malissen B, Dagorn JC, Iovanna JL and Dusetti NJ: TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. J Biol Chem. 278:37722–37729. 2003. View Article : Google Scholar : PubMed/NCBI
7	Weng W, Yang Q, Huang M, Qiao Y, Xie Y, Yu Y, jing A and Li Z: c-Myc inhibits TP53INP1 expression via promoter methylation in esophageal carcinoma. Biochem Biophys Res Commun. 405:278–284. 2011. View Article : Google Scholar : PubMed/NCBI
8	Jiang PH, Motoo Y, Garcia S, Iovanna JL, Pébusque MJ and Sawabu N: Down-expression of tumor protein p53-induced nuclear protein 1 in human gastric cancer. World J Gastroenterol. 12:691–696. 2006. View Article : Google Scholar : PubMed/NCBI
9	Ito Y, Motoo Y, Yoshida H, Iovanna JL, Takamura Y, Miya A, Kuma K and Miyauchi A: Decreased expression of tumor protein p53-induced nuclear protein 1 (TP53INP1) in breast carcinoma. Anticancer Res. 26:4391–4395. 2006.PubMed/NCBI
10	Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, et al: Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA. 104:16170–16175. 2007. View Article : Google Scholar : PubMed/NCBI
11	Bonazzi VF, Irwin D and Hayward NK: Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma. Genes Chromosomes Cancer. 48:10–21. 2009. View Article : Google Scholar : PubMed/NCBI
12	Ito Y, Motoo Y, Yoshida H, Iovanna JL, Nakamura Y, Kuma K and Miyauchi A: High level of tumour protein p53-induced nuclear protein 1 (TP53INP1) expression in anaplastic carcinoma of the thyroid. Pathology. 38:545–547. 2006. View Article : Google Scholar : PubMed/NCBI
13	Giusiano S, Baylot V, Andrieu C, Fazli L, Gleave M, Iovanna JL, TarangerCharpin C, Garcia S and Rocchi P: TP53INP1 as new therapeutic target in castration-resistant prostate cancer. Prostate. 72:1286–1294. 2012. View Article : Google Scholar : PubMed/NCBI
14	Li WG and Wang HQ: Inhibitory effects of Silibinin combined with doxorubicin in hepatocellular carcinoma; an in vivo study. J BUON. 21:917–924. 2016.PubMed/NCBI
15	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
16	Center MM and Jemal A: International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 20:2362–2368. 2011. View Article : Google Scholar : PubMed/NCBI
17	European association for the study of the liver; European organisation for research and treatment of cancer, . EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 56:908–943. 2012. View Article : Google Scholar : PubMed/NCBI
18	Edmondson HA and Steiner PE: Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI
19	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
20	Pinder SE, Brown JP, Gillett C, Purdie CA, Speirs V, Thompson AM and Shaaban AM: Translational Subgroup of the NCRI Breast Clinical Studies Group: The manufacture and assessment of tissue microarrays: Suggestions and criteria for analysis, with breast cancer as an example. J Clin Pathol. 66:169–177. 2013. View Article : Google Scholar : PubMed/NCBI
21	Carrier A, Nguyen C, Victorero G, Granjeaud S, Rocha D, Bernard K, Miazek A, Ferrier P, Malissen M, Naquet P, et al: Differential gene expression in CD3epsilon- and RAG1-deficient thymuses: Definition of a set of genes potentially involved in thymocyte maturation. Immunogenetics. 50:255–270. 1999. View Article : Google Scholar : PubMed/NCBI
22	Gommeaux J, Cano C, Garcia S, Gironella M, Pietri S, Culcasi M, Pébusque MJ, Malissen B, Dusetti N, Iovanna J, et al: Colitis and colitis-associated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1. Mol Cell Biol. 27:2215–2228. 2007. View Article : Google Scholar : PubMed/NCBI
23	Taïeb D, Giusiano S, Sebag F, Marcy M, de Micco C, Palazzo FF, Dusetti NJ, Iovanna JL, Henry JF, Garcia S, et al: Tumor protein p53-induced nuclear protein (TP53INP1) expression in medullary thyroid carcinoma: A molecular guide to the optimal extent of surgery? World J Surg. 34:830–835. 2010. View Article : Google Scholar : PubMed/NCBI
24	Giusiano S, Garcia S, Andrieu C, Dusetti NJ, Bastide C, Gleave M, TarangerCharpin C, Iovanna JL and Rocchi P: TP53INP1 overexpression in prostate cancer correlates with poor prognostic factors and is predictive of biological cancer relapse. Prostate. 72:117–128. 2012. View Article : Google Scholar : PubMed/NCBI
25	Seux M, Peuget S, Montero MP, Siret C, Rigot V, Clerc P, Gigoux V, Pellegrino E, Pouyet L, N'Guessan P, et al: TP53INP1 decreases pancreatic cancer cell migration by regulating SPARC expression. Oncogene. 30:3049–3061. 2011. View Article : Google Scholar : PubMed/NCBI
26	Seillier M, Peuget S, Gayet O, Gauthier C, N'Guessan P, Monte M, Carrier A, Iovanna JL and Dusetti NJ: TP53INP1, a tumor suppressor, interacts with LC3 and ATG8-family proteins through the LC3-interacting region (LIR) and promotes autophagy-dependent cell death. Cell Death Differ. 19:1525–1535. 2012. View Article : Google Scholar : PubMed/NCBI